News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-03 EDT			5-day change	1st Jan Change
15.38 ^USD	-6.90%		-31.83%	-1.91%

07-31	Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial	MT
07-31	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT

All News

Mentions Relevance

07-31	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
07-02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI
06-29	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Value Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000 Growth Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Small Cap Comp Value Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark	CI
06-28	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark	CI
06-02	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05-20	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
05-07	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
05-07	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05-05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04-21	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	PU
04-20	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	GL
04-20	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	CI